AFF008E:Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE PD01A Applied During AFF008 in Patients With Parkinson's Disease.

Trial Profile

AFF008E:Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE PD01A Applied During AFF008 in Patients With Parkinson's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Affitope PD01 (Primary) ; Aluminium oxide
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 26 Feb 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
    • 26 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top